Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen;Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terapéutica

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 2, 2004, Pages 106-112

  Knobel, Hernando ^a   Guelar, Ana ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Adherence; Antiretroviral treatment; Compliance; HIV; Interventions

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE;

DIET RESTRICTION; DRUG DOSE REGIMEN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW;

EID: 2342462396     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(04)73044-X     Document Type: Review

References (108)

1. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. En: Sackett DL, Haynes RB, eds. Compliance with therapeutic regimens. Baltimore: Johns Hopkins Univ Pr, 1976; p. 11-27.
2. Paterson DL, Swindells S, Mohr J, Brester M, Michelle RN, Vergis EN, et al. Adherence to Protease Inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
3. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-1.
4. Bennett D, Zaidi I, Heneine W. Prevalence of mutations associated with antiretroviral drug resistance among recently diagnosed persons with HIV, 1998-2000. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 372.
5. Grant RM, Kahn JO, Warmerdam M. Transmission and transmissibility of drug resistant HIV-1. Acute infection: Resistance, fitness, and transmission. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 368.
6. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Convay B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-7.
7. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antirretroviral therapy (HAART). Lancet 1998;351:723-4.
8. Fatkenheur G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-F6.
9. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21.
10. Nieuwkerk P, Gisolf E, Sprangers M, Danner S. Adherence over 48 weeks in an antiretraviral clinical trial: Variable within patients, affected by toxicities and independently predictive of virological response. Antivir Ther 2001;6:97-103.
11. Le MV, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002;16:21-29.
12. Knobel H, Guelar A, Carmona A, Espona M, González A, López-Colomes JL, et al. Virologic outcome and predictors of virological failure on highly active antiretroviral therapy containing protease inhibitors in a cohort of HIV-infected patients. AIDS Patient Care STDS 2001;15:193-9.
13. Lucas G, Chaisson R, Moore R. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:897-904.
14. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3.
15. th International AIDS Conference. Durban, Sudáfrica. 2000 (abstract MoPeD2556).
16. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10.
17. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality atbaseline and after 1 year of follow-up. AIDS 2002;16:1051-8.
18. Valenti WM. HIV management: New technologies improve outcome and contain costs. AIDS Read 2002;12:64-6.
19. Ammassari A, Trota MP, Murri R, Castelli F, Narciso P, Noto P, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002;31: S123-7.
20. Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, et al. Compliance with zidovudine therapy in patients infected with HIV: A cross sectional study in a municipal hospital clinic. Am J Med 1992;92:495-502.
21. Bartlett JA. Addresing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(Suppl 1):2-10.
22. Turner BJ. Adherence to antiretroviral therapy by Human Immunodeficiency Virus-infected patients. Clin Infec Dis 2001;33:865-72.
23. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and Pneumocystis prophilaxis in HIV disease. J Acquir Immune Defic Syndr 1998;18:117-25.
24. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
25. Chesney MA, Ickoviks JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS care 2000;12:255-66.
26. Gordillo V, Del Amo J, Soriano V, González-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-9.
27. Tuldrá A, Fumaz C, Ferrer M, Bayes R, Arno A, Balague M, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active anti-retroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-8.
28. Metha S, Moore RD, Graham NHM. Potential factors affecting adherence with HIV therapy. AIDS 1997;11:1665-70.
29. Stone V, Hogan J, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients understanding their regimens: Survey of women in the HER study. J Acquir Immune Defic Syndr 2001;28:124-31.
30. Chesney M. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 2):171-6.
31. Gallant J, Block D. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients. J Int Asc Phys AIDS Care 1998;4:32-5.
32. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
33. Bartlett JA, Demasi R, Quin J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral naive HIV-1 infected adults. AIDS 2001;15:1369-77.
34. Ammassari A, Murri R, Pezotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherenceto highly active antirotroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-9.
35. Durán S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001;15:2441-4.
36. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-95.
37. Knobel H. ¿Cómo y porqué debe monitorizarse la adherencia al tratamiento antirretroviral en la actualidad? Enferm Infecc Microbiol Clin 2002;20:481-3.
38. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002;31(Suppl 3):103-6.
39. Knobel H, Codina C, Miro JM, Carmona A, García B, Antela A, et al. Recomendaciones de GESIDA/SEFH/PNS para mejorar la adherencia del tratamiento antirretroviral. Enferm Infecc Microbiol Clin 2000;18:27-39.
40. Rubio R, Berenguer J, Miró JM, Antela A, Iribarren JA, González J, et al. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. Enferm Infecc Microbiol Clin 2002;20:244-303.
41. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV. Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents. Ann Intern Med 2002;137:381-433.
42. Morgenstern T, Grimes D, Grimes R. Assessment of readiness to initiate antiretroviral therapy. HIV Clin Trials 2002;3:168-72.
43. Grimes RM, Lal L, Lewis ST. Frequency of medical history items, drug interactions, and lifestyle characteristics that may interfere with antiretroviral medications. HIV Clin Trials 2002;3:161-7.
44. Friedland GH, Andrews LA. Adherence to antiretroviral therapy. AIDS Reviews 2001;3:111-20.
45. Mushlin AI, Appel FA. Diagnosing potential noncompliance. Physicians' ability in a behavioral dimension of medical care. Arch Intern Med 1977;137:318-21.
46. Moyle GJ. The once-a-day era is upon us. AIDS Read 2002;12:56-58.
47. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in antirretroviral-naïve HIV-infected adults. A randomized equivalence trial. JAMA 2001;285:1155-63.
48. th Conference on Retroviruses and Opportunistic Infections. Seattle, USA. 2002 (abstract 543).
49. nd ICAAC. San Diego, Ca, USA. 2002 (abstract: O-1101).
50. nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July 2003. Antiviral Therapy 2003;8(Suppl 1):194.
51. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Pérez P, Pérez JL, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002;7:81-90.
52. Staszewski S, Morales-Ramírez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults: Study 006 Team. N Engl J Med 1999;341:1865-73.
53. Ribera E, Aguirrebengoa K, Miralles C, Antela A, Ribero A, Arribas JR. Simplificación del tratamiento antirretreviral. Enferm Infecc Microbiol Clin 2002;20(Supl 2):48-57.
54. Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
55. Dieleman JP, Gyssens IC, Sturkenboom MJCM, Niesters HGM, Van der Ende ME. Substituting nevirapine for protease inhibitors because of intolerance. AIDS 1999;13:1423-4.
56. Barreiro P, Soriano V, Blanco F, Casimiro C, De la Cruz JJ, González-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
57. Raffi F, Bonnet B, Ferié V, Esnault JL, Perre P, Reliquet V, et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000;31:1274-8.
58. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36.
59. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
60. Martínez E, García-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-73.
61. Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Krantz V, De Mautort E, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001;27:459-62.
62. Knechten H, Stürner KH, Höhn C, Braun P. Switch to efavirenz in a protease inhibitor-containing regimen. HIV Clinical Trials 2001;2:200-4.
63. Hirschel B, Flepp M, Bucher HC, Zellweger C, Telenti A, Wagels T, et al. Switching from protease inhibitors to efavirenz: Differences in efficacy and tolerance among risk groups: A case-control study from the Swiss HIV Cohort. AIDS 2002;16:381-5.
64. Clumeck N, Goebel F, Rozembaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
65. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60.
66. Masquelier B, Neau D, Chêne G, Larbere J, Birac V, Ragnaud JM, et al. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J AIDS 2001;28:309-12.
67. Dieleman JP, Sturkenboom MCJM, Wit FW, Jambroes M, Mulder JW, Ten Veen JH, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis 2002;185:1261-8.
68. th CROI. Seattle, Feb 24-28 2002. Abstract: LB17.
69. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, et al. TRIZAL study: Switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86.
70. Becker S, Rachlis A, Gill J. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads. A prospective, randomized, multicenter, open-label study (DMP 049). En: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 20.
71. Knobel H, Guelar A, Vallecillo G, Carmona A, Saballs P, González A, et al. Simplified antiretroviral therapy with zidovudine, lamivudine and abacavir as salvage therapy for heavily non-adherents patients. XIV International AIDS Conference; July 7-12, 2002. Abstract [WePeB5829].
72. Boyle BA. Efficacy and safety of once-daily antiretroviral therapy. AIDS Read 2002;12:90-6.
73. Rosenbach KA, Allison R, Nadler J. Daily dosing of Highly Active Antiretroviral Therapy. Clin Infect Dis 2002;34:686-92.
74. Luber AD. The push for once-daily HAART: A call for caution. Medscape HIV/AIDS ejournal 2002;8(3).
75. Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V, Gute P. A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Medicine 2000;1:162-3.
76. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;82:599-602.
77. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001;6:249-53.
78. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS. 2003;17:1017-22.
79. nd ICAAC. San Diego, Ca, USA 2002 (abstrast: H-163).
80. th Conference on Retroviruses and Opportunistic Infections, Boston, Feb 10-14, 2003; abstract 564b.
81. nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13-16 July 2003 (abstract 38) Antiviral Therapy 2003;(Supl 1):193.
82. Barreiro P, Soriano V, Casas E, González-Lahoz J. Different degree of immune recovery in HIV-infected patients receiving antiretroviral regimens containing protease inhibitors or non-nucleosides. AIDS 2002;16:245-9.
83. Kempf D, Marsh K, Kumar G, Rodrigues AD, Denissen JF, McDonald E, et al. Pharmacokinetic enhancement of inhibitors of the HIV protease by co-administration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
84. Mallolas J, Blanco JL, Sarasa M, Giner V, Martínez E, García-Viejo MA, et al. Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudina in HIV-infected patients. J Acquir Immune Defic Syndr 2000;25:229-35.
85. Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr 2001;27:260-5.
86. Cardiello PG, Van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 Study. J Acquir Immune Defic Syndr 2002;29:464-70.
87. Montaner JSG, Saag MS, Barylski C. FOCUS study: Saquinavir QD versus efavirenz QD regimen 48 week analysis in HIV infected patients. Program and abstracts of the 42th ICAAC; September 27-30, 2002; San Diego, California. Abstract H-167.
88. th Conference on Retroviruses and Opportunistic Infections. Chicago, EUA. 2001 (abstract 332).
89. th Conference on Retroviruses and Opportunistic Infections. Seattle, EUA. 2002 (abstract 126).
90. th Conference on Retroviruses and Opportunistic Infections. Seattle, EUA. 2002 (abstract 706).
91. nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1076, 2002.
92. th International Congress on Drug Therapy in HIV Infection. 17-22 Novembere 2002. Glasgow, UK. Abstract P-99.
93. Glaxo Smith Kline letter (July 2003). Early Virologic Non-Response in Patients with HIV Infection Treated With Lamivudine, Abacavir and Tenofovir.
94. Urquhard J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J 1992;68(3):S49-S59.
95. Levy G. A pharmacokinetic perspective on medication noncompliance. Clin Pharmacol Ther 1993;54:242-4.
96. Stone VE. Enhancing adherence to antiretrovirals: Strategies and regimens. Medscape HIV/AIDS ejournal 2002;8(4).
97. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: A critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr 2002;31(Suppl 3):98-102.
98. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: A work in progress. Clin Infect Dis 2002;34:984-90.
99. Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T, Graham NM, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis 2002;34:511-8.
100. Stenzel MS, McKenzie M, Mitty JA, Flanagan T. Enhancing adherence to HAART: Modified directly observed therapy. AIDS Reader 2001;11:317-28.
101. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed anti-retroviral therapy for injection drug users with HIV infection. AIDS Read 2002;12:305-16.
102. Mitty JA, Macalino G, Taylor L, Harwell JI, Flanigan TP. Directly observed therapy (DOT) for individuals with HIV: Successes and challenges. Med Gen Med 2003;5:30.
103. th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 545.
104. Knobel H, Carmona A, López JL, Gimeno JL, Saballs P, González A, et al. Adherencia al tratamiento antirretroviral de gran actividad: impacto de una intervención de asesoramiento individualizado. Enferm Infecc Microbiol Clin 1999;17:78-81.
105. Tuldrá A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31(Suppl 3):154-7.
106. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications (Cochrane Review). En: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
107. Peterson AM, Takiya L, Finley R. Meta-Analysis of Trials of Interventions to Improve Medication Adherence. Am J Health-Syst Pharm 2003;60:657-65.
108. Sabundayo BP. Report on adherence from the XIV International Conference in Barcelona. The Hopkins HIV Report 2002;14(6).